C4 Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 3.04M | $7.98M | 0.01% | Added+101.1% | 2026-03-31 |
| RenTech | quant | 2.46M | $6.47M | 0.01% | Added+53.6% | 2026-03-31 |
| DEShaw | quant | 1.06M | $2.79M | 0.00% | Added+1905.2% | 2026-03-31 |
| StateStreet | passive | 383.0K | $1.01M | 0.00% | Added+11.7% | 2026-03-31 |
| FidelityFMR | fundamental | 272.4K | $716.33K | 0.00% | Added+7.1% | 2026-03-31 |
| Citadel | multi-strat | 169.1K | $444.72K | 0.00% | Trimmed-98.2% | 2026-03-31 |
| TRowePrice | fundamental | 71.5K | $189 | 0.00% | Added+477.0% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.24 | — | — |
| 2026-05-12 | -0.26 | -0.20 | +23.08% |
| 2026-02-26 | -0.39 | -0.18 | +54.24% |
| 2025-11-06 | -0.41 | -0.44 | -7.68% |
| 2025-08-07 | -0.38 | -0.37 | +3.27% |
| 2025-05-07 | -0.43 | -0.37 | +13.56% |
| 2025-02-27 | -0.45 | -0.49 | -8.80% |
| 2024-10-31 | -0.33 | -0.35 | -7.14% |
| 2024-08-01 | -0.18 | -0.26 | -44.44% |
| 2024-05-08 | -0.26 | -0.38 | -46.95% |
| 2024-02-22 | -0.69 | -0.68 | +1.41% |
| 2023-11-01 | -0.65 | -0.54 | +17.88% |
| 2023-08-08 | -0.69 | -0.73 | -5.56% |
| 2023-05-04 | -0.75 | -0.71 | +5.08% |
| 2023-02-23 | -0.59 | -0.76 | -29.90% |
| 2022-11-03 | -0.61 | -0.65 | -7.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CCCC | +49.66% | +48.14% | +128.80% | +249.60% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +46.69% | +52.77% | +132.24% | +236.91% |